Investigation of the Effects of Oxidized Antigens on the T-Cell Response and the Epigenetic Reprogramming of Neutrophils in Lung Diseases - OXIGENE -
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Characterization of the neutrophil granulocyte epigenome, Characterization of the T-cell immune response to to various oxidatively modified mycobacterial antigens.
- Who it may be relevant to
- Registry conditions: Asthma, COPD, Bacterial Pneumonia, Viral Pneumonia. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Germany
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The OXIGENE study is a research project that aims to better understand how the immune system behaves in people with lung diseases such as asthma, COPD, pneumonia, tuberculosis, and viral lung infections. By analyzing a single blood sample, the study examines how certain immune cells react during inflammation and infection, and whether lasting changes in these cells influence how strongly the body responds to disease. Although participants do not receive direct medical benefit, the results may help improve future diagnosis and treatment of lung diseases by providing deeper insight into immune responses.
Detailed description
The OXIGENE study is an observational research project that explores how the human immune system responds in different lung diseases, including asthma, COPD, pneumonia, tuberculosis, and viral lung infections such as COVID-19 or influenza. The study focuses on two key components of the immune system: neutrophils, which are among the first immune cells to respond to inflammation, and T cells, which play an important role in longer-term immune defense. Researchers investigate whether neutrophils show lasting changes in their behavior during lung disease and how these changes may differ depending on the type of illness or individual patient characteristics. In people with tuberculosis, the study also examines whether chemical changes to bacterial proteins caused by inflammation influence how strongly T cells are activated.
Participation in the study involves a single blood draw, similar to a routine blood test, with no medications, interventions, or follow-up visits required. The study does not provide direct medical benefit to participants, but the risks are minimal and limited to those associated with blood sampling. By improving the understanding of how immune responses are altered in lung diseases, the OXIGENE study aims to generate knowledge that could support the development of better diagnostic tools and more targeted treatments for future patients.
Interventions
- Other Characterization of the neutrophil granulocyte epigenome
Characterization of epigenomic differences in neutrophils from patients with different lung diseases (asthma, COPD, pneumonia, tuberculosis, and viral pulmonary infections such as COVID-19 and influenza) by identifying disease-specific epigenetic and functional signatures - Other Characterization of the T-cell immune response to to various oxidatively modified mycobacterial antigens
Investigation of the response (activation/stimulation) of antigen-specific T cells from patients with tuberculosis to various oxidatively modified mycobacterial antigens, with the aim of determining whether changes in the redox status of these antigens measurably influence the adaptive immune response.
Primary outcome measures
- Characterization of the neutrophil granulocyte epigenome [Time frame: 2030]
- Characterization of functional signatures [Time frame: 2030]
Secondary outcome measures (2)
- Influence of demographic and clinical variables [Time frame: 2030]
- Identification of subgroups within diseases [Time frame: 2030]
Eligibility criteria
Inclusion criteria
- Diagnosis of an acute or chronic inflammatory lung disease, infectious or non-infectious, including asthma, COPD, pneumonia, tuberculosis, or viral pulmonary infection (e.g., COVID-19, influenza).
- Age ≥ 18 years at the time of informed consent.
- Ability to provide informed consent and consent to the collection and processing of clinical and laboratory data, as well as to the analysis of blood samples as part of study participation.
- Sufficient physical condition to undergo a single venous blood draw (approximately 50 mL), as assessed by the treating physician.
Exclusion criteria
- Active malignant disease or ongoing cancer therapy (e.g., chemotherapy or immunotherapy), due to potential immunological confounding.
- Immunosuppressive therapy or known severe immunodeficiency that could interfere with the interpretation of cellular immune responses.
- Pregnancy or breastfeeding, for general research-ethical reasons and to protect vulnerable populations.
- Acute unstable clinical condition that, in the opinion of the treating physician, makes study participation unreasonable.
- Known intolerance to blood sampling or relevant hematological disorders that could compromise the safety or feasibility of venipuncture.
- Lack of capacity to provide informed consent or insufficient understanding of the study content despite supportive explanation.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Germany · 2 centers
- Medical Service Center MVZ, Research Center Borstel, Leibniz Lung Center — Borstel
- Department of Pulmonology, University Hospital Schleswig-Holstein — Kiel
Identifiers
NCT: NCT07386912 · OXIGENE